CLINICAL_TRIALS
trial_result
· 2020-02-19
Clinical Trial Update: Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction [Phase 3]
Summary
Phase 3 trial evaluating apatinib in combination with concurrent neoadjuvant chemoradiotherapy for gastroesophageal junction adenocarcinoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hebei Medical University | Conditions: Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: UNKNOWN